Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) - Trial NCT03134222
Access comprehensive clinical trial information for NCT03134222 through Pure Global AI's free database. This Phase 2 trial is sponsored by Gilead Sciences and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 47 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Gilead Sciences
Timeline & Enrollment
Phase 2
May 24, 2017
Dec 18, 2019
Primary Outcome
Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12
Summary
The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib
 (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus
 erythematosus (CLE).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03134222
Non-Device Trial